Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427644 | 1.00 | METAP2 (0.33) | METAP2ACACBMAPTTDP1CYP1A2 | |
| SCHEMBL14348143 | 1.00 | METAP2 (0.33) | METAP2ACACBMAPTTDP1CYP1A2 | |
| SCHEMBL14348151 | 0.94 | METAP2 (0.39) | METAP2ALDH1A1MAPK1REN | |
| SCHEMBL8424741 | 0.94 | METAP2 (0.39) | METAP2ALDH1A1MAPK1REN | |
| SCHEMBL8242020 | 0.83 | METAP2 (0.33) | METAP2REN | |
| SCHEMBL8426448 | 0.83 | TDP1 (0.32) | METAP2ACACBTDP1CYP1A2CYP2D6 | |
| SCHEMBL14348147 | 0.83 | TDP1 (0.32) | METAP2ACACBTDP1CYP1A2CYP2D6 | |
| SCHEMBL14117623 | 0.83 | METAP2 (0.33) | METAP2REN | |
| SCHEMBL8427664 | 0.82 | ACACB (0.33) | METAP2ACACBMAPTTDP1CYP1A2 | |
| SCHEMBL14348564 | 0.82 | ACACB (0.33) | METAP2ACACBMAPTTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | METAP2 3809/4885ACACB 629/4885MAPT 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.